R S Wallis
Overview
Explore the profile of R S Wallis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rachow A, Ivanova O, Bakuli A, Khosa C, Nhassengo P, Owolabi O, et al.
Int J Tuberc Lung Dis
. 2023 Oct;
27(11):850-857.
PMID: 37880896
Spirometry is considered relevant for the diagnosis and monitoring of post-TB lung disease. However, spirometry is rarely done in newly diagnosed TB patients. Newly diagnosed, microbiologically confirmed TB patients were...
2.
Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson E, et al.
Trials
. 2023 Jun;
24(1):382.
PMID: 37280643
Background: Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy....
3.
Migliori G, Marx F, Ambrosino N, Zampogna E, Schaaf H, van der Zalm M, et al.
Int J Tuberc Lung Dis
. 2021 Oct;
25(10):797-813.
PMID: 34615577
Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD...
4.
Allwood B, van der Zalm M, Amaral A, Byrne A, Datta S, Egere U, et al.
Int J Tuberc Lung Dis
. 2020 Sep;
24(8):820-828.
PMID: 32912387
ALTHOUGH CURABLE, TB frequently leaves the individual with chronic physical and psycho-social impairment, but these consequences have been largely neglected. The 1 International Post-Tuberculosis Symposium (Stellenbosch, South Africa) was held...
5.
Davies G, Wallis R
Int J Tuberc Lung Dis
. 2017 Feb;
20(12):13-17.
PMID: 28240567
Predicting the required duration of treatment necessary to yield an acceptable risk of recurrence is a key question facing Phase III trials in both drug-susceptible (DS) and multidrug-resistant tuberculosis (MDR-TB)....
6.
Solovic I, Sester M, Gomez-Reino J, Rieder H, Ehlers S, Milburn H, et al.
Eur Respir J
. 2010 Jun;
36(5):1185-206.
PMID: 20530046
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who...
7.
Wallis R, Broder M, Wong J, Hanson M, Beenhouwer D
Clin Infect Dis
. 2004 May;
38(9):1261-5.
PMID: 15127338
The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food...
8.
Wallis R, Johnson J
Curr Opin Pulm Med
. 2001 May;
7(3):124-32.
PMID: 11371767
This article reviews the significant advances in the past year in the basic and clinical aspects of adult tuberculosis (TB). Further research has deepened our understanding of host susceptibility and...
9.
Wallis R, Palaci M, Vinhas S, Hise A, Ribeiro F, Landen K, et al.
J Infect Dis
. 2001 Mar;
183(8):1300-3.
PMID: 11262217
The bactericidal activity of orally administered antituberculosis (anti-TB) drugs was determined in a whole blood culture model of intracellular infection in which microbial killing reflects the combined effects of drug...
10.
Wallis R, Phillips M, Johnson J, Teixeira L, Rocha L, Maciel E, et al.
Antimicrob Agents Chemother
. 2001 Mar;
45(4):1302-4.
PMID: 11257053
Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse. In this trial, rifampin or rifalazil inhibited the...